On the other hand, the median survival from the start of treatment administration was 4.08 (95% CI: 1.59-NA) years for patients who had immunotherapy for their NSCLC but not ALK or EGFR mutation-related targeted therapy, and 1.70 (95% CI: 1.30-NA) years for patients who did not have immunotherapy or ALK or EGFR mutation-related targeted therapy (Figure 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.